A three-year utilization analysis of branded second-generation antipsychotics at a regional health plan

In the last 30 years,13 new antipsychotic entities have been approved by the Food and Drug Administration (FDA). Today, the majority of those are available generically. Caplyta (lumateperone), Fanapt (Iloperidone), Rexulti (brexpiprazole), Vraylar (cariprazine), and the most recently approved, Lybalvi (olanzapine/samidorphan), continue to be available only as brand name products. The cost of antipsychotics in 2023 was $18.04 billion USD. It is anticipated that this market will continue to increase at about eight percent annually, reaching $37.40 billion by 2032